{"entity":{"id":"nct05701306","kind":"trial","name":"APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of APG-115 in neuroblastoma, run by Ascentage Pharma Group Inc., now recruiting.","summary":"APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors is a phase 1/2 interventional study registered as NCT05701306 by Ascentage Pharma Group Inc., with 100 participants planned, started 2023-02-28 and due to reach its primary completion in 2027-06-01. Interventions recorded: APG-115 and APG-2575.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05701306","url":"https://clinicaltrials.gov/study/NCT05701306"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ascentage-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05701306","phase":"1/2","setting":"A Phase Ib-ⅡClinical Study of APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors","sponsor":"Ascentage Pharma Group Inc.","enrolled":100,"outcomes":[]},"route":"/trials/nct05701306/","neighbours":{"cancer":[{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"company":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/"}]}}